SummaryThis trial will run across two treatment arms. In Treatment Arm 1, eligible patients will receive HDM201 in combination with MBG453. In Treatment Arm 2, patients will receive HDM201 in combination with venetoclax, which will be gradually increased (ramp-up) over a period of 4 to 5 days to achieve the daily target dose tested that will be subsequently continued.
Treatment TypeSystemic therapy (chemotherapy, hormone therapy or immunotherapy)
Use the hyperlinks, where available to access additional clinical trial information.
A Phase Ib, Multi-arm, Open-label, Study of HDM201 in Combination With MBG453 or Venetoclax in Adult Subjects With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)